Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine March 2014, 55 (3) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

Aptamer-based imaging: Wang and Farokhzad provide an overview of the use of these single-stranded oligonucleotides as targeting ligands and their application in molecular diagnosis and therapy.

Page 353

Occult primary NET imaging: Schillaci looks at radiopharmaceuticals available for imaging unknown primary neuroendocrine tumors and previews an article in this issue of JNM on the advantages of 18F-DOPA PET/CT in this setting.

Page 357

Safety of repeated radioembolization: Zarva and colleagues assess the safety of repeated 90Y radioembolization with resin microspheres in patients with extensive primary and secondary liver tumors after failure of first radioembolization.

Page 360

18F-FDOPA and NETs of unknown origin: Imperiale and colleagues evaluate the performance of 18F-DOPA PET/CT in detecting and further characterizing primary neuroendocrine tumors not seen on other morphologic or functional imaging.

Page 367

PET/CT vs PET/MR in lung cancer staging: Heusch and colleagues compare a dedicated pulmonary 18F-FDG PET/MR imaging protocol with 18F-FDG PET/CT for primary and locoregional lymph node staging in patients with non–small cell lung cancer.

Page 373

Preoperative PET and NSCLC: Zeliadt and colleagues examine the real-world effectiveness of PET in avoiding unnecessary surgery in patients newly diagnosed with non–small cell lung cancer.

Page 379

PET/CT and KRAS mutations: Miles and colleagues explore the potential for multifunctional imaging to provide a signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog gene mutations in human colorectal cancer.

Page 386

PET/CT in noninfected vascular grafts: Keidar and colleagues describe the incidence and patterns of 18F-FDG uptake over time in noninfected vascular grafts, with a focus on prosthetic material and location.

Page 392

PET imaging of VAChT: Petrou and colleagues report on human imaging with 18F-FEOBV, a vesamicol derivative that binds selectively to the vesicular acetylcholine transporter, and detail radiation dosimetry, biodistribution, safety, brain kinetics, and quantitative analysis methods.

Page 396

Monte Carlo dosimetry for SIRT: Petitguillaume and colleagues present a 3D dosimetry technique based on patient-specific data for optimization of personalized Monte Carlo dosimetry in 90Y selective internal radiation therapy for unresectable hepatic cancer.

Page 405

Tumor texture, SUV, and volume in PET: Orlhac and colleagues investigate texture indices derived from gray-level histograms and their relationship with standardized uptake value, metabolic tumor volume, and total lesion glycolysis in 3 different tumor types.

Page 414

PET and NMDA receptors: McGinnity and colleagues characterize the kinetic behavior of 18F-GE-179, a novel radioligand that selectively binds to the open/active state of the N-methyl d-aspartate receptor channels, which play a key role in a range of neurologic processes.

Page 423

PET/CT and HPV+ OPSCC: Subramaniam and colleagues provide an educational overview of the evolving role of 18F-FDG PET/CT in the management of patients with human papilloma virus–positive oropharyngeal squamous cell cancer.

Page 431

Propranolol and18F-FDG uptake inhibition: Kang and colleagues explore the relationship between activation of β-adrenoceptors and expression of glucose transporter–1 and hexokinase-2 and discuss the potential effects of this relationship on 18F-FDG PET imaging in breast cancer.

Page 439

Integrin αvβ3 in pancreatic cancer: Trajkovic-Arsic and colleagues report on the unexplored potential of αvβ3 integrin–targeted multimodal molecular imaging for detection of pancreatic ductal adenocarcinoma in genetically engineered mouse models.

Page 446

ImmunoPET with anti-PSCA minibody: Knowles and colleagues detail the development and validation of agents using 124I- and 89Zr-labeled anti–prostate stem cell antigen A11 minibodies and evaluate their use for quantitative immunoPET imaging of prostate cancer.

Page 452

Serotonergic metabolism in pancreas: Eriksson and colleagues investigate the feasibility of quantitative noninvasive imaging of serotonergic metabolism in the endocrine pancreas using the PET tracer 11C-5-HTP.

Page 460

Imaging microglial activation: Dickens and colleagues describe a reproducible lipopolysaccharide-induced model of acute central nervous system inflammation and compare the performance of 18F-GE-180, a translocator protein ligand, with that of 11C-(R)-PK11195 in detection of activated microglial cells and astrocytes.

Page 466

Imaging MC-I in the brain: Tsukada and colleagues evaluate a novel probe for quantitative PET assessment of mitochondria complex 1 activity and associated ischemic damage in the living brain.

Page 473

Estrogen receptor imaging in rats: Khayum and colleagues determine whether estrogen receptors can be measured in the rat brain with 18F-FES PET and whether tracer uptake is affected by endogenous estrogen.

Page 481

Improved complexes for hypoxia imaging: Handley and colleagues report on evaluation and performance of 2 promising 64Cu-ATSM analog complexes for PET imaging of hypoxic myocardium.

Page 488

Small-animal PET with isolated perfused heart: Yamane and colleagues report on a technique combining the Langendorff method of isolated rat heart perfusion with high-resolution small-animal PET to facilitate reliable quantification of myocardial tracer kinetics.

Page 495

TEM1 immuno-PET: Chacko and colleagues detail the preparation and evaluation of a novel 124I-labeled humanized monoclonal antibody, looking at its ability to specifically and sensitively detect vascular cells expressing tumor endothelial marker 1 in vivo.

Page 500

XTEN-annexin A5: Haeckel and colleagues present a method to extend imaging probe blood life with a long-circulating hydrophilic peptide without PEGylation, thereby simplifying synthesis and avoiding inactivation of annexin A5 and potential adverse effects of polyethylene glycol.

Page 508

Comparison of 4 PET hypoxia tracers: Carlin and colleagues compare the imaging characteristics and hypoxia selectivity of 4 PET radiotracers in a murine xenograft tumor model using small-animal PET imaging and combined ex vivo autoradiography and fluorescence immunohistochemistry.

Page 515

  • © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 55 (3)
Journal of Nuclear Medicine
Vol. 55, Issue 3
March 1, 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Mar 2014, 55 (3) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Mar 2014, 55 (3) 8A;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Multifunctional Imaging Signature for V-KI-RAS2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations in Colorectal Cancer
  • Development of 124I Immuno-PET Targeting Tumor Vascular TEM1/Endosialin
  • Detection of Microglial Activation in an Acute Model of Neuroinflammation Using PET and Radiotracers 11C-(R)-PK11195 and 18F-GE-180
  • A Comparison of the Imaging Characteristics and Microregional Distribution of 4 Hypoxia PET Tracers
  • Cardiac Hypoxia Imaging: Second-Generation Analogues of 64Cu-ATSM
  • Thoracic Staging in Lung Cancer: Prospective Comparison of 18F-FDG PET/MR Imaging and 18F-FDG PET/CT
  • Three-Dimensional Personalized Monte Carlo Dosimetry in 90Y Resin Microspheres Therapy of Hepatic Metastases: Nontumoral Liver and Lungs Radiation Protection Considerations and Treatment Planning Optimization
  • Current Progress of Aptamer-Based Molecular Imaging
  • Quantitative ImmunoPET of Prostate Cancer Xenografts with 89Zr- and 124I-Labeled Anti-PSCA A11 Minibody
  • 18F-FDG Uptake in Noninfected Prosthetic Vascular Grafts: Incidence, Patterns, and Changes over Time
  • 18F-DOPA and Other Radiopharmaceuticals for Imaging Unknown Primary Neuroendocrine Tumors
  • Safety of Repeated Radioembolizations in Patients with Advanced Primary and Secondary Liver Tumors and Progressive Disease After First Selective Internal Radiotherapy
  • PET/CT Imaging and Human Papilloma Virus–Positive Oropharyngeal Squamous Cell Cancer: Evolving Clinical Imaging Paradigm
  • In Vivo Imaging of Brain Estrogen Receptors in Rats: A 16α-18F-Fluoro-17β-Estradiol PET Study
  • In Vivo Imaging of Human Cholinergic Nerve Terminals with (–)-5-18F-Fluoroethoxybenzovesamicol: Biodistribution, Dosimetry, and Tracer Kinetic Analyses
  • Novel PET Probes 18F-BCPP-EF and 18F-BCPP-BF for Mitochondrial Complex I: A PET Study in Comparison with 18F-BMS-747158-02 in Rat Brain
  • Multimodal Molecular Imaging of Integrin αvβ3 for In Vivo Detection of Pancreatic Cancer
  • Small-Animal PET Imaging of Isolated Perfused Rat Heart
  • XTEN-Annexin A5: XTEN Allows Complete Expression of Long-Circulating Protein-Based Imaging Probes as Recombinant Alternative to PEGylation
  • Tumor Texture Analysis in 18F-FDG PET: Relationships Between Texture Parameters, Histogram Indices, Standardized Uptake Values, Metabolic Volumes, and Total Lesion Glycolysis
  • Quantitative Imaging of Serotonergic Biosynthesis and Degradation in the Endocrine Pancreas
  • Preoperative PET and the Reduction of Unnecessary Surgery Among Newly Diagnosed Lung Cancer Patients in a Community Setting
  • Propranolol Inhibits Glucose Metabolism and 18F-FDG Uptake of Breast Cancer Through Posttranscriptional Downregulation of Hexokinase-2
  • 18F-Fluorodihydroxyphenylalanine PET/CT in Patients with Neuroendocrine Tumors of Unknown Origin: Relation to Tumor Origin and Differentiation
  • Initial Evaluation of 18F-GE-179, a Putative PET Tracer for Activated N-Methyl d-Aspartate Receptors
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire